Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioNexus Gene Lab's book value per share for the quarter that ended in Mar. 2026 was $3.35.
During the past 12 months, BioNexus Gene Lab's average Book Value Per Share Growth Rate was -22.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -4.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of BioNexus Gene Lab was 52.00% per year. The lowest was -8.20% per year. And the median was 5.40% per year.
BioNexus Gene Lab's current price is $1.66. Its book value per share for the quarter that ended in Mar. 2026 was $3.35. Hence, today's PB Ratio of BioNexus Gene Lab is 0.50.
During the past 8 years, the highest P/B Ratio of BioNexus Gene Lab was 301.93. The lowest was 0.44. And the median was 3.16.
Good Sign:
BioNexus Gene Lab Corp stock PB Ratio (=0.5) is close to 1-year low of 0.5.
BioNexus Gene Lab (NAS:BGLC) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
BioNexus Gene Lab Book Value per Share Related Terms
BioNexus Gene Lab Book Value per Share Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLC vs QGAI, VYST, GLGI: Book Value per Share Comparison
For the Specialty Chemicals subindustry, BioNexus Gene Lab's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab PB Ratio vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a Book Value per Share of $3.35 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on BioNexus Gene Lab and its competitors.
Is BioNexus Gene Lab's Book Value per Share too high?
BioNexus Gene Lab's current Book Value per Share is $3.35. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's Book Value per Share compare to QGAI and VYST?
BioNexus Gene Lab's Book Value per Share of $3.35 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Chemicals company?
A good Book Value per Share depends on the Chemicals industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on BioNexus Gene Lab and its competitors. BioNexus Gene Lab's current Book Value per Share is $3.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.66 — trading 23.5% below its estimated fair value. The current Book Value per Share is $3.35. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current Book Value per Share is $3.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.66 is trading 23.5% below its estimated GF Value™ of $2.17.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
Book Value per Share: $3.35
GF Value™: $2.17 vs. price of $1.66 (23.5% below fair value)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
